Myeloproliferative Neoplasm — Research

Myeloproliferative Neoplasm — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed14 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-28	54,279	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh])`	2026-09-28	pubmed
Last 5 years	2021-01-01 → 2026-12-31	6,431	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-28	pubmed
Preceding 5-year window	2020-09-28 → 2025-09-27	5,977	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2020/09/28:2025/09/27[dp])`	2026-09-28	pubmed
Last 12 months	2025-09-28 → 2026-09-28	907	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2025/09/28:2026/09/28[dp])`	2026-09-28	pubmed
y2016	2016-01-01 → 2016-12-31	1,668	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2016/01/01:2016/12/31[dp])`	2026-09-28	pubmed
y2017	2017-01-01 → 2017-12-31	1,546	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2017/01/01:2017/12/31[dp])`	2026-09-28	pubmed
y2018	2018-01-01 → 2018-12-31	1,470	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2018/01/01:2018/12/31[dp])`	2026-09-28	pubmed
y2019	2019-01-01 → 2019-12-31	1,501	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2019/01/01:2019/12/31[dp])`	2026-09-28	pubmed
y2020	2020-01-01 → 2020-12-31	1,538	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2020/01/01:2020/12/31[dp])`	2026-09-28	pubmed
y2021	2021-01-01 → 2021-12-31	1,514	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2021/01/01:2021/12/31[dp])`	2026-09-28	pubmed
y2022	2022-01-01 → 2022-12-31	1,451	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2022/01/01:2022/12/31[dp])`	2026-09-28	pubmed
y2023	2023-01-01 → 2023-12-31	1,345	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2023/01/01:2023/12/31[dp])`	2026-09-28	pubmed
y2024	2024-01-01 → 2024-12-31	1,241	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2024/01/01:2024/12/31[dp])`	2026-09-28	pubmed
y2025	2025-01-01 → 2025-12-31	960	`("Myeloproliferative Disorders"[mh] OR "Disorder, Myeloproliferative"[mh]) AND (2025/01/01:2025/12/31[dp])`	2026-09-28	pubmed

Data updated 3 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (206)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 176–200 of 206 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
· Invest New Drugs · 2017 · PMID 28516360 · validated civic_curation pubmed
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
· Leukemia · 2013 · PMID 22858906 · validated civic_curation pubmed
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
· Blood · 2006 · PMID 16434489 · validated civic_curation pubmed
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.